Navigation Links
Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
Date:6/4/2010

G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender Time: 2:00 PM - 6:00 PM Location: S Hall A2 Date: Saturday, June 5, 2010 POSTER PRESENTATION - Abstract # 561 Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van 't Veer Time: 2:00 PM - 6:00 PM Location: S Hall A2 Date: Monday, June 7, 2010 POSTER DISCUSSION - Abstract # 1520 Effect of screening on the detection of good and poor prognosis breast cancers Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S. Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer Time: 2:00 PM - 6:00 PM / 5:00 PM - 6:00 PM (discussion in E451b) Location: E450b Colon Cancer Date: Monday, June 7, 2010 POSTER PRESENTATION - Abstract # TPS199 The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke Holzik, J. Tabernero, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg Time: 8:00 AM - 12:00 PM Location: S Hall A2 Date: Tuesday, June 8, 2010 POSTER DISCUSSION - Abstract # 3513 Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I. Simon, K. Janssen, H. Friess Time: 11:00 AM - 12:00 PM Location: S 406 (Vista Room)

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
2. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
3. Agendia Raises US $23 Million in Series E Financing
4. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
5. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
6. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
7. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
8. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
9. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
10. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BRIDGEWATER, N.J. , July 24, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today announces receipt of notice on July ... that the NYSE-MKT has accepted the CorMedix plan ... the NYSE-MKT. As a result, the NYSE-MKT is ...
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... to also Raise $7.5 Million in Non-Dilutive Financing from, ... 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) ... a definitive agreement, subject to shareholder and regulatory approvals, whereby ... and merger to continue as a publicly-traded entity to be ...
... , SHANGHAI, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... leading Chinese firm,specializing in the manufacture, research, development, marketing and,distribution ... quarter of its 2010 fiscal year, ended June 30, 2009. ... -- Net sales increased 35.5% year-over-year to $15.4 ...
... a "spaser," is the first of its kind to ... possible future technologies based on "nanophotonic" circuitry, said Vladimir ... and Computer Engineering at Purdue University. Such circuits ... be made small enough to integrate them into electronic ...
Cached Biology Technology:Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 3Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 4Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 5Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 6Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 7Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 8Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11New nanolaser key to future optical computers and technologies 2New nanolaser key to future optical computers and technologies 3
(Date:7/24/2014)... smog-free Los Angeles, where electric cars ply silent freeways, ... heat from beneath the earth, from howling winds and ... study finds that it is technically and economically feasible ... by clean, renewable energy. Published in Energy , ... and reliable energy supply in California that could create ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... too much growth in patients has now also been ... can lead to very different conditions, according to research ... IMAGe* syndrome is a rare developmental disorder which ... body and organ size. Without treatment, the disorder can ...
... climate change because they don,t understand the science behind ... more proficient in technical reasoning, would public consensus match ... the journal Nature Climate Change suggests that ... members of the public become more science literate and ...
... see how a common house sparrow and a Tyrannosaurus Rex might ... weighs less than an ounce, and the other is a dinosaur ... scales at more than eight tons. For all their ... than many believed. A new study, led by Harvard scientists, has ...
Cached Biology News:Variations of a single gene can lead to too much or too little growth, study shows 2Yale study concludes public apathy over climate change unrelated to science literacy 2Timing is everything 2Timing is everything 3Timing is everything 4
... use with dishes and cell culture clusters. ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ... Comp Dim: blade L 1.9 cm handle ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
Biology Products: